切换至 "中华医学电子期刊资源库"
高级检索
中华细胞与干细胞杂志(电子版)

中华细胞与干细胞杂志(电子版) ›› 2023, Vol. 13 ›› Issue (02) : 87 -92. doi: 10.3877/cma.j.issn.2095-1221.2023.02.004

综述

间充质干细胞治疗炎性关节炎的研究进展
冯星, 靳洪涛, 马隽, 宋永周, 刘爱京†()   
  1. 050000　石家庄，河北医科大学第二医院风湿免疫科
    050000　石家庄，河北医科大学解剖教研室；050000　石家庄，河北省干细胞医学转化工程研究中心
    050000　石家庄，河北医科大学第二医院骨科；050000　石家庄，河北省干细胞医学转化工程研究中心
    050000　石家庄，河北医科大学第二医院风湿免疫科；050000　石家庄，河北省干细胞医学转化工程研究中心
  • 收稿日期:2021-11-14 出版日期:2023-04-01
  • 通信作者: 刘爱京

Progress in the treatment of inflammatory arthritis with mesenchymal stem cells

Xing Feng, Hongtao Jin, Jun Ma, Yongzhou Song, Aijing Liu†()   

  1. Department of Rheumatology and Immunology, the Second Hospital of Hebei Medical University, Shijiazhuang 050000, China
    Department of Anatomy, Hebei Medical University, Shijiazhuang 050000, China; Hebei Stem Cell Medical Transformation Engineering Research Center, Shijiazhuang 050000, China
    Department of Orthopedics, the Second Hospital of Hebei Medical University, Shijiazhuang 050000, China; Hebei Stem Cell Medical Transformation Engineering Research Center, Shijiazhuang 050000, China
    Department of Rheumatology and Immunology, the Second Hospital of Hebei Medical University, Shijiazhuang 050000, China; Hebei Stem Cell Medical Transformation Engineering Research Center, Shijiazhuang 050000, China
  • Received:2021-11-14 Published:2023-04-01
  • Corresponding author: Aijing Liu
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

冯星, 靳洪涛, 马隽, 宋永周, 刘爱京. 间充质干细胞治疗炎性关节炎的研究进展[J/OL]. 中华细胞与干细胞杂志(电子版), 2023, 13(02): 87-92.

Xing Feng, Hongtao Jin, Jun Ma, Yongzhou Song, Aijing Liu. Progress in the treatment of inflammatory arthritis with mesenchymal stem cells[J/OL]. Chinese Journal of Cell and Stem Cell(Electronic Edition), 2023, 13(02): 87-92.

炎性关节炎（IA）是一组可累及多关节的慢性炎症性疾病，包括强直性脊柱炎、类风湿关节炎和银屑病关节炎等，早期诊断和治疗对患者预后尤为关键。目前临床主要治疗药物以非甾体类抗炎药、缓解病情抗风湿药以及靶向合成药物为主，但仍有部分患者存在疗效差、易复发和副作用大的问题。近年来，间充质干细胞（MSCs）因来源广泛、易获取、分化能力强、免疫调节及抗炎等优点被越来越多应用于IA的治疗。本文对MSCs治疗IA的作用机制、来源、剂量、给药方式和疗效等进行综述，旨在为IA的治疗提供新思路。

关键词: 炎性关节炎, 间充质干细胞, 细胞治疗

Inflammatory arthritis (IA) is a group of chronic inflammatory diseases that influence multiple joints, including ankylosing spondylitis, rheumatoid arthritis, psoriatic arthritis, and so on. And early diagnosis and treatment are critical for the prognosis of patients. Currently, non-steroidal anti-inflammatory drugs, disease-modifying anti-rheumatic drugs, and biological agents are the main clinical drugs. However, some patients still suffer from poor efficacy, recurrence, and side effects. In recent years, mesenchymal stem cells (MSCs) have been increasingly applied in treating IA due to their advantages, such as various sources, easy access, strong differentiation potential, and immunomodulatory and anti-inflammatory abilities. This article reviewed the mechanisms, sources, dosages, administration methods, and efficacy of MSCs in treating IA, aiming to provide new ideas for the treatment of IA.

Key words: Inflammatory arthritis, Mesenchymal stem cells, Cell therapy
表1 纳入文献的基本特征
IA病种 第一作者 样本量 MSCs种类 输注方式 输注次数 随访时间 疗效 不良反应
AS Li [20] 5 UC-MSCs 静脉注射 1 ~ 3次 1年 有效 一过性轻微发热
AS 曲海洪[21] 30 UC-MSCs 局部注射 1次 6个月 有效 无
RA合并AS 王黎明[22] 2 UC-MSCs 静脉+局部注射 1次 4 ~ 14个月 有效 无
RA álvaro-Gracia [28] 53 AD-MSCs 静脉注射 3次 6个月 有效 感染、发热、腔隙性脑梗死等
RA Ghoryani [29] 9 BM-MSCs 静脉注射 1次 12个月 有效 无
PSA De Jesus [43] 1 AD-MSCs 静脉注射 2次 12个月 不明显 无
PSA Coutts [44] 1 UC-MSCs 静脉+关节腔注射 2次 12个月 有效 流感样症状
SLE关节炎 朱宁[50] 18 UC-MSCs 静脉注射 2次 3个月 有效 无
SLE关节炎 白茹[51] 10 UC-MSCs 静脉注射 3 ~ 5次 3年 有效 输注过程中发热、呕吐
JIA Swart [59] 6 BM-MSCs 静脉注射 1 ~ 2次 3个月 有效 无
JIA Wang [60] 10 UC-MSCs 静脉注射 2次 2年 有效 无
1
Poudel P, Goyal A, Bansal P, et al. Inflammatory arthritis[M]. StatPearls, 2020.
2
Sewerin P, Brinks R, Schneider M, et al. Prevalence of rheumatoid arthritis and spondyloarthritis in turkey: a nationwide study[J]. Arch Rheumatol, 2017, 33(2):128-136.
3
潘显阳. 痛风性关节炎发病的炎性机制研究进展[J]. 安徽医科大学学报, 2021, 56(7):1167-1171.
4
Hansildaar R, Vedder D, Baniaamam M, et al. Cardiovascular risk in inflammatory arthritis: rheumatoid arthritis and gout[J]. Lancet Rheumatol, 2021, 3(1):e58-e70.
5
Chiu YM, Chen DY. Infection risk in patients undergoing treatment for inflammatory arthritis: non-biologics versus biologics[J]. Expert Rev Clin Immunol, 2020, 16(2):207-228.
6
Pistoia V, Raffaghello L. Mesenchymal stromal cells and autoimmunity[J]. Int Immunol, 2017, 29(2):49-58.
7
Yagyu T, Yasuda S, Nagaya N, et al. Long-term results of intracardiac mesenchymal stem cell transplantation in patients with cardiomyopathy[J]. Circ J, 2019, 83(7):1590-1599.
8
Pixley JS. Mesenchymal stem cells to treat type 1 diabetes[J]. Biochim Biophys Acta Mol Basis Dis, 2020, 1866(4):165315. doi: 10.1016/j.bbadis.2018.10.033.
9
Deng L, Peng Q, Wang H, et al. Intrathecal injection of allogenic bone marrow-derived mesenchymal stromal cells in treatment of patients with severe ischemic stroke: study protocol for a randomized controlled observer-blinded trial[J]. Transl Stroke Res, 2019, 10(2):170-177.
10
Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The international society for cellular therapy position statement[J]. Cytotherapy, 2006, 8(4):315-317.
11
Han Y, Li X, Zhang Y, et al. Mesenchymal stem cells for regenerative medicine[J]. Cells, 2019, 8(8):886. doi: 10.3390/cells8080886.
12
Magatti M, Vertua E, De Munari S, et al. Human amnion favours tissue repair by inducing the M1-to-M2 switch and enhancing M2 macrophage features[J]. J Tissue Eng Regen Med, 2017, 11(10):2895-2911.
13
Magatti M, Vertua E, Cargnoni A, et al. The immunomodulatory properties of amniotic cells: the two sides of the coin[J]. Cell Transplant, 2018, 27(1):31-44.
14
Yang X, Yang J, Li X, et al. Bone marrow-derived mesenchymal stem cells inhibit T follicular helper cell in lupus-prone mice[J]. Lupus, 2018, 27(1):49-59.
15
Khosravi M, Bidmeshkipour A, Moravej A, et al. Induction of CD4+CD25+Foxp3+ regulatory T cells by mesenchymal stem cells is associated with RUNX complex factors[J]. Immunol Res, 2018, 66(1):207-218.
16
MacDonald GI, Augello A, De Bari C. Role of mesenchymal stem cells in reestablishing immunologic tolerance in autoimmune rheumatic diseases[J]. Arthritis Rheum, 2011, 63(9):2547-2557.
17
Nauta AJ, Fibbe WE. Immunomodulatory properties of mesenchymal stromal cells[J]. Blood, 2007, 110(10):3499-3506.
18
Cosenza S, Toupet K, Maumus M, et al. Mesenchymal stem cells-derived exosomes are more immunosuppressive than microparticles in inflammatory arthritis[J]. Theranostics, 2018, 8(5):1399-1410.
19
Fu X, Liu G, Halim A, et al. Mesenchymal stem cell migration and tissue repair[J]. Cells, 2019, 8(8):784. doi: 10.3390/cells8080784.
20
Li A, Tao Y, Kong D, et al. Infusion of umbilical cord mesenchymal stem cells alleviates symptoms of ankylosing spondylitis[J]. Exp Ther Med, 2017, 14(2):1538-1546.
21
曲海洪, 李晓昊, 张军. 不同剂量脐带间充质干细胞在针刀镜下定植治疗强直性脊柱炎患者病变髋关节的临床观察[J]. 国际感染杂志（电子版）, 2019, 8(2):67-69.
22
王黎明, 周建军, 白雯, 等. 脐带间充质干细胞治疗17例类风湿性关节炎患者的临床疗效观察[J]. 中国免疫学杂志, 2017, 7:659-662.
23
François RJ, Neure L, Sieper J, et al. Immunohistological examination of open sacroiliac biopsies of patients with ankylosing spondylitis: detection of tumour necrosis factor α in two patients with early disease and transforming growth factor beta in three more advanced cases[J]. Ann Rheum Dis, 2006, 65(6):713-720.
24
Xie Z, Wang P, Li J, et al. MCP1 triggers monocyte dysfunctions during abnormal osteogenic differentiation of mesenchymal stem cells in ankylosing spondylitis[J]. J Mol Med (Berl), 2017, 95(2):143-154.
25
米汝佳, 蔡兆鹏, 苏鸿君, 等. 肿瘤坏死因子α对强直性脊柱炎患者间充质干细胞成骨分化的影响[J]. 免疫学杂志, 2020, 36(3):254-259.
26
Calabresi, E, Petrelli F, Bonifacio AF, et al. One year in review 2018: pathogenesis of rheumatoid arthritis[J]. Clin Exp Rheumatol, 2018, 36(2):175-184.
27
Liu L, Wong CW, Han M, et al. Meta-analysis of preclinical studies of mesenchymal stromal cells to treat rheumatoid arthritis[J]. EBioMedicine, 2019, 47:563-577.
28
álvaro-Gracia JM, Jover JA, García-Vicuña R, et al. Intravenous administration of expanded allogeneic adipose-derived mesenchymal stem cells in refractory rheumatoid arthritis (Cx611): results of a multicentre, dose escalation, randomised, single-blind, placebo-controlled phase Ib/IIa clinical trial[J]. Ann Rheum Dis, 2017, 76(1):196-202.
29
Ghoryani M, Shariati-Sarabi Z, Tavakkol-Afshari J, et al. Amelioration of clinical symptoms of patients with refractory rheumatoid arthritis following treatment with autologous bone marrow-derived mesenchymal stem cells: a successful clinical trial in Iran[J]. Biomed Pharmacother, 2019, 109:1834-1840.
30
Feng Z, Zhai Y, Zheng Z, Yang L, et al. Loss of A20 in BM-MSCs regulates the Th17/Treg balance in Rheumatoid Arthritis[J]. Sci Rep, 2018, 8(1):427. doi: 10.1038/s41598-017-18693-0.
31
Zheng J, Zhu L, Iok In I, et al. Bone marrow-derived mesenchymal stem cells-secreted exosomal microRNA-192-5p delays inflammatory response in rheumatoid arthritis[J]. Int Immunopharmacol, 2020, 78:105985. doi: 10.1016/j.intimp.2019.105985.
32
Zhang Q, Li Q, Zhu J, et al. Comparison of therapeutic effects of different mesenchymal stem cells on rheumatoid arthritis in mice[J]. PeerJ, 2019, 7:e7023. doi: 10.7717/peerj.7023.
33
侯婧瑛, 于萌蕾, 郭天柱, 等. 缺氧预处理激活HIF-1α/MALAT1/VEGFA通路促进骨髓间充质干细胞生存和血管再生[J]. 中国组织工程研究, 2021, 25(7):985-990.
34
Ankrum JA, Dastidar RG, Ong JF, et al. Performance-enhanced mesenchymal stem cells via intracellular delivery of steroids[J]. Sci Rep, 2014, 4:4645. doi: 10.1038/srep04645.
35
Gossec L,Baraliakos X, Kerschbaumer A, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update[J]. Ann Rheum Dis, 2020, 79(6):700 712.
36
Chandran V, Schentag CT, Brockbank JE, et al. Familial aggregation of psoriatic arthritis[J]. Ann Rheum Dis, 2009, 68(5):664-667.
37
Nair RP, Stuart PE, Nistor I, et al. Sequence and haplotype analysis supports HLA-C as the psoriasis susceptibility 1 gene[J]. Am J Hum Genet, 2006, 78(5):827-851.
38
Brewerton DA, Caffrey M, Nicholls A, et al. HL-A 27 and arthropathies associated with ulcerative colitis and psoriasis[J]. Lancet, 1974, 1(7864):956-8.
39
Qian Y, Liu C, Hartupee J, et al. The adaptor Act1 is required for interleukin 17-dependent signaling associated with autoimmune and inflammatory disease[J]. Nat Immunol, 2007, 8(3):247-256.
40
杨琴,张改连,温晓婷,等.银屑病关节炎治疗新进展[J].中华风湿病学杂志, 2020, 24(01):64-67.
41
王方迪,侯瑞霞,赵新程,等.银屑病患者血清对真皮间充质干细胞基因表达及功能的影响[J].中国免疫学杂志, 2021, 37(15):1867-1871.
42
Castro-Manrreza ME, Bonifaz L, Castro-Escamilla O, et al. Mesenchymal stromal cells from the epidermis and dermis of psoriasis patients: morphology, immunophenotype, differentiation patterns, and regulation of T cell proliferation[J]. Stem Cells Int, 2019, 2019:4541797. doi: 10.1155/2019/4541797.
43
De Jesus MM, Santiago JS, Trinidad CV, et al. Autologous adipose-derived mesenchymal stromal cells for the treatment of psoriasis vulgaris and psoriatic arthritis: A case report[J]. Cell Transplant, 2016, 25(11):2063-2069.
44
Coutts M, Soriano R, Naidoo R, et al. Umbilical cord blood stem cell treatment for a patient with psoriatic arthritis[J]. World J Stem Cells, 2017, 9(12):235-240.
45
Braiteh F, Hymes SR, Giralt SA, et al. Complete remission of psoriasis after autologous hematopoietic stem-cell transplantation for multiple myeloma[J]. J Clin Oncol, 2008, 26(27):4511-4513.
46
桑雨婷,朱芸,马晶晶,等.银屑病关节炎患者皮损进展与血清总IgE及IL-6、TNF-α水平的关系[J]. 中国现代医生, 2020, 58(3):12-15.
47
Zoma A. Musculoskeletal involvement in systemic lupus erythematosus[J]. Lupus, 2004, 13(11):851-853.
48
Drenkard C, Bao G, Dennis G, et a1.The burden of systemic lupus erythematosus on employment and work productivity: data from a large cohort in the southeastern United States[J]. Arthritis Care Res (Hoboken), 2014, 66(6):878-887．
49
耿研,李伯睿,张卓莉.系统性红斑狼疮患者有症状关节病变的肌肉骨骼超声特点[J]. 北京大学学报（医学版）, 2020, 52(1):163-168.
50
朱宁,毛静,张小莲,等.脐带间充质干细胞移植在系统性红斑狼疮患者中的应用研究[J].疑难病杂志, 2016, 15(1):44-47.
51
白茹,戚燕,吕昭萍,等.脐带间充质干细胞移植治疗难治性系统性红斑狼疮3年随访[J].中国免疫学杂志, 2017, 33(6):905-909.
52
中华医学会风湿病学分会,中国医院协会临床新技术应用专业委员会.异体间充质干细胞治疗系统性红斑狼疮专家共识[J].中华风湿病学杂志, 2022, 26(1):1-8.
53
Yuan X, Qin X, Wang D, et al. Mesenchymal stem cell therapy induces FLT3L and CD1c+ dendritic cells in systemic lupus erythematosus patients[J]. Nat Commun, 2019, 10(1):2498. doi: 10.1038/s41467-019-10491-8.
54
丁会玲. 脐带间充质干细胞联合利妥昔单抗治疗系统性红斑狼疮临床研究[J]. 临床研究, 2016, 24(7):10-11.
55
Li D, Li X, Duan M,et al. MiR-153-3p induces immune dysregulation by inhibiting PELI1 expression in umbilical cord-derived mesenchymal stem cells in patients with systemic lupus erythematosus[J]. Autoimmunity, 2020, 53(4):201-209.
56
Cheng RJ, Xiong AJ, Li YH, et al. Mesenchymal stem cells: allogeneic MSC may be immunosuppressive but autologous MSC are dysfunctional in lupus patients[J]. Front Cell Dev Biol, 2019, 7:285. doi: 10.3389/fcell.2019.00285.
57
Martini A, Ravelli A, Avcin T, et al. Pediatric Rheumatology International Trials Organization (PRINTO). Toward new classification criteria for juvenile idiopathic arthritis: first steps, Pediatric Rheumatology International Trials Organization International Consensus[J]. J Rheumatol, 2019, 46(2):190-197.
58
Marzetti V, Breda L, Miulli E, et al. Clinical characteristics of juvenile idiopathic arthritis in an area of central Italy: a population-based study[J]. Ann Ig, 2017, 29(4):281-292.
59
Swart JF, de Roock S, Nievelstein RAJ, et al. Bone-marrow derived mesenchymal stromal cells infusion in therapy refractory juvenile idiopathic arthritis patients[J]. Rheumatology, 2019, 58(10):1812-1817.
60
Wang L, Zhang Y, Li H, et al. Clinical observation of employment of umbilical cord derived mesenchymal stem cell for juvenile idiopathic arthritis therapy[J]. Stem Cells Int, 2016, 2016:9165267. doi: 10.1155/2016/9165267.
61
Orczyk K, Smolewska E. Are we right to consider mesenchymal stem cells to be a new perspective for patients with juvenile idiopathic arthritis?[J]. Arch Immunol Ther Exp (Warsz), 2018, 66(4):267-271.
[1] 曹胜军, 李全, 符雪, 邵天喜, 周延华. 人脂肪间充质干细胞多层膜片对促进裸鼠皮肤缺损愈合的效果观察[J/OL]. 中华损伤与修复杂志(电子版), 2024, 19(04): 341-347.
[2] 傅红兴, 王植楷, 谢贵林, 蔡娟娟, 杨威, 严盛. 间充质干细胞促进胰岛移植效果的研究进展[J/OL]. 中华细胞与干细胞杂志(电子版), 2024, 14(06): 351-360.
[3] 王大伟, 陆雅斐, 皇甫少华, 陈玉婷, 陈澳, 江滨. 间充质干细胞通过调控免疫机制促进创面愈合的研究进展[J/OL]. 中华细胞与干细胞杂志(电子版), 2024, 14(06): 361-366.
[4] 袁园园, 岳乐淇, 张华兴, 武艳, 李全海. 间充质干细胞在呼吸系统疾病模型中肺组织分布及治疗机制的研究进展[J/OL]. 中华细胞与干细胞杂志(电子版), 2024, 14(06): 374-381.
[5] 王俊楠, 刘晔, 李若涵, 叶青松. 间充质干细胞调控肠脑轴治疗神经系统疾病的潜力[J/OL]. 中华细胞与干细胞杂志(电子版), 2024, 14(05): 313-319.
[6] 陈俊秋, 邬绿莹, 马予洁, 林娜, 刘飞, 陈津. 基于lncRNA微阵列芯片技术探索间充质干细胞外泌体增强小鼠胰岛β细胞抗低氧损伤的潜在机制[J/OL]. 中华细胞与干细胞杂志(电子版), 2024, 14(03): 129-136.
[7] 杨阳, 王琤, 周文土, 周冰. Caveolae/Caveolin-1与膜胆固醇共同调控小鼠BMSCs成骨分化[J/OL]. 中华细胞与干细胞杂志(电子版), 2024, 14(03): 137-142.
[8] 孙海燕, 周士燕, 张杉杉, 张研, 张茜. 间充质干细胞及其外泌体在高原肺水肿中的潜在治疗机制研究进展[J/OL]. 中华细胞与干细胞杂志(电子版), 2024, 14(03): 186-190.
[9] 凌淑洵, 涂玥, 刘思逸. 间充质干细胞在慢性肾脏病研究领域现状和趋势的知识图谱可视化分析[J/OL]. 中华细胞与干细胞杂志(电子版), 2024, 14(02): 73-82.
[10] 王娟, 刘晔, 熊威, 蒋财磊, 贺燕, 叶青松. 间充质干细胞缓解阿尔茨海默病氧化应激的新思路[J/OL]. 中华细胞与干细胞杂志(电子版), 2024, 14(02): 93-106.
[11] 梁国豪, 张茜, 张研. 间充质干细胞及其衍生物治疗高原低氧环境下心血管疾病的研究进展[J/OL]. 中华细胞与干细胞杂志(电子版), 2024, 14(02): 107-112.
[12] 景水力, 王娟, 刘晔, 周亨, 熊威, 叶青松. 间充质干细胞在脊髓损伤中的应用及研究进展[J/OL]. 中华细胞与干细胞杂志(电子版), 2024, 14(02): 113-121.
[13] 陆雅斐, 皇甫少华, 马传学, 江滨. 间充质干细胞治疗肛瘘手术方式的研究进展[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(03): 242-249.
[14] 史敬萱, 焦圆圆, 田景玮, 卓莉. 间充质干细胞来源外泌体治疗动物糖尿病肾脏病的效果：Meta分析[J/OL]. 中华肾病研究电子杂志, 2024, 13(02): 79-86.
[15] 汪鹏飞, 程莹莹, 赵海康. 骨髓间充质干细胞改善神经病理性疼痛的机制探讨[J/OL]. 中华脑科疾病与康复杂志(电子版), 2024, 14(04): 230-234.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号

AI
小
编
AI小编
你好！我是《中华医学电子期刊资源库》AI小编，有什么可以帮您的吗？